Nitesh Pratap¹*, Ravi Shankar B², Bharani I³, Santosh N⁴ and Sameer Kumar⁵

¹Department of Medical Gastroenterology, KIMS Hospitals, Secunderabad India
²Department of Medical Gastroenterology, Yashoda Hospitals, Secunderabad, India
³Department of Medical Gastroenterology, Apollo Hospitals, Secunderabad, India
⁴Department of Medical Gastroenterology, Medicover Hospitals, Hi-tech City, India
⁵Department of Medical Gastroenterology, Gleneagles Hospitals, India

*Corresponding Author: Nitesh Pratap, Department of Medical Gastroenterology, KIMS Hospitals, Secunderabad India.

Received: March 27, 2025; Published: March 31, 2025

Abstract

Irritable Bowel Syndrome (IBS) is a multifactorial gastrointestinal disorder characterized by abdominal pain, bloating and altered bowel habits. Small intestinal bacterial overgrowth (SIBO) has emerged as a potential contributor to IBS pathophysiology. This review aims to elaborate the relationship between SIBO and IBS explaining the association, consequences, diagnostic approach and therapeutic strategies. Prevalence of SIBO in IBS shows a wide variation with higher estimates at 25 - 80%. Though symptoms of SIBO are classical, it is still sometimes difficult to diagnose. The gold standard test is jejunal aspirate and analysis of small bowel flora, but is cumbersome. Glucose hydrogen breath test (GHBT) and/or lactulose hydrogen breath test (LaHBT) can be screening tests and are practically easy to carry out. Treatment often includes antibiotics, probiotics and dietary intervention

Keywords: IBS; SIBO; ROME IV; Dysbiosis; Rifaximin; Probiotics

References

1. Bull Michael J and Nicole T Plummer. "Part 1: The Human Gut Microbiome in Health and Disease”. Integrative Medicine (Encinitas) 13.6 (2014): 17-22.
2. Menees Stacey and William Chey. "The Gut Microbiome and Irritable Bowel Syndrome”. F1000 Research 7 (2018).
3. Drossman Douglas A and William L Hasler. "Rome IV-Functional GI Disorders:Disorders of Gut-Brain Interaction”. Gastroenterology6 (2016): 1257-1261.
4. Ghoshal Uday Chand and Uday C Ghoshal. "Small Intestinal Bacterial Overgrowth and Other Intestinal Disorders”. Gastroenterology Clinics of North America1 (2017): 103-120.
5. Takakura Waku and Mark Pimentel. "Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome - An Update”. Frontiers in Psychiatry 11 (2020).
6. Ghoshal Uday Chand., et al. "Indian Consensus Statements on Irritable Bowel Syndrome in Adults: A Guideline by the Indian Neurogastroenterology and Motility Association and Jointly Supported by the Indian Society of Gastroenterology”. Indian Journal of Gastroenterology2 (2023): 249-273.
7. Ghoshal Uday Chand., et al. "Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome: A Bridge Between Functional Organic Dichotomy”. Gut and Liver2 (2017): 196-208.
8. Ghoshal Uday Chand and D Srivastava. "Irritable Bowel Syndrome and Small Intestinal Bacterial Overgrowth: Meaningful Association or Unnecessary Hype”. World Journal of Gastroenterology10 (2014): 2482-2491.
9. Sachdeva S., et al. "Small Intestinal Bacterial Overgrowth (SIBO) in Irritable Bowel Syndrome: Frequency and Predictors”. Journal of Gastroenterology and Hepatology3 (2011): 135-138.
10. Pimentel Mark, et al. "Normalization of Lactulose Breath Testing Correlates with Symptom Improvement in Irritable Bowel Syndrome: A Double-Blind, Randomized, Placebo-Controlled Study”. The American Journal of Gastroenterology2 (2003): 412-419.
11. Ghoshal Uday Chand., et al. "A Proof-of-Concept Study Showing Antibiotics to Be More Effective in Irritable Bowel Syndrome with than without Small-Intestinal Bacterial Overgrowth: A Randomized, Double-Blind, Placebo-Controlled Trial”. European Journal of Gastroenterology and Hepatology3 (2016): 281-289.
12. Pimentel Mark., et al. "Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation”. The New England Journal of Medicine1 (2011): 22-32.
13. Pimentel Mark., et al. "Lower Frequency of MMC Is Found in IBS Subjects with Abnormal Lactulose Breath Test, Suggesting Bacterial Overgrowth”. Digestive Diseases and Sciences 47 (2002): 2639-2643.
14. Pimentel Mark., et al. "Low-Dose Nocturnal Tegaserod or Erythromycin Delays Symptom Recurrence after Treatment of Irritable Bowel Syndrome Based on Presumed Bacterial Overgrowth”. Gastroenterology and Hepatology 6 (2009): 435.
15. Lacy Brian E., et al. "Bowel Disorders”. Gastroenterology 6 (2016): 1393-1407.
16. Rezaie Ali., et al. "Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus”. The American Journal of Gastroenterology5 (2017): 775-784.
17. Pimentel Mark., et al. "SIBO: A Common Cause of IBS and GERD”. Journal of Clinical Gastroenterology6 (2018): 537-543.
18. Ghoshal Uday Chand., et al. "Asian-Pacific Consensus on Small Intestinal Bacterial Overgrowth in Gastrointestinal Disorders: An Initiative of the Indian Neurogastroenterology and Motility Association”. Indian Journal of Gastroenterology5 (2022): 483-507.

Citation

Citation: Nitesh Pratap., et al. “Small Intestinal Bacterial Overgrowth in Irritable Bowel Syndrome: Consequences, Diagnosis and Treatment".Acta Scientific Gastrointestinal Disorders 8.4 (2025): 57-61.

Copyright

Copyright: © 2025 Nitesh Pratap., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.